News

Investor's Business Daily on MSN3d

Why Replimune's Surprise Rejection Rattled Wall Street, And Cratered Its Stock

Replimune stock cratered Tuesday after the Food and Drug Administration unexpectedly rejected its experimental melanoma ...
PharmExec21h

Replimune CRL Fallout: How Biopharma Leaders Should Manage a New Layer of FDA Uncertainty

A deep dive into the implications of the Replimune CRL that surprised insiders and investors, the role of new leadership at ...

Replimune stock plunges after FDA rejects melanoma treatment application

Investing.com -- Replimune Group, Inc. (NASDAQ: REPL) stock plunged 77% after the company announced it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) ...

Replimune Stock Plummets 75% After FDA Rejects Application for Skin Cancer Treatment

Replimune said the agency had issued a complete response letter regarding the company’s biologics license application for RP1 ...

Replimune plunges as FDA rejects its lead drug for skin cancer

Replimune (REPL) stock in focus as the FDA rejects its lead drug RP1 as part of a combination regimen for melanoma, a type of ...

Replimune rebounds despite analyst downgrades on FDA rejection

Replimune (REPL) stock rebounds even as FDA rejection of its RP1 skin cancer drug lead to multiple analyst downgrades on Wall Street. Read more here.

FDA Rejects Replimune's Blood Cancer Drug, Stock Sinks

Replimune stock fell after the FDA rejected its RP1 application, citing flaws in the trial design and lack of substantial evidence for approval.
TMCnet2d

REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Replimune Group, Inc. ("Replimune" or "the Company") (NASDAQ: REPL) for ...